For Monoclonal Antibodies, Compliance with the Written Description Requirement Has Become a Moving Target

Abstract

Biotechnology Law ReportVol. 36, No. 6 Holman ReportFor Monoclonal Antibodies, Compliance with the Written Description Requirement Has Become a Moving TargetChristopher M. HolmanChristopher M. HolmanSearch for more papers by this authorPublished Online:1 Dec 2017https://doi.org/10.1089/blr.2017.29043.cmhAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byAmgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies Christopher M. Holman15 December 2022 | Biotechnology Law Report, Vol. 41, No. 6How a Dosage Regimen Patent for RRMS Treatment May Satisfy the Written Description Requirement—A Lesson from Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc. PING-HSUN CHEN11 October 2022 | Biotechnology Law Report, Vol. 41, No. 5Enablement Invoked as a “Super-Written Description Requirement” to Overturn $2.5 Billion Jury Verdict Christopher M. Holman1 April 2018 | Biotechnology Law Report, Vol. 37, No. 2 Volume 36Issue 6Dec 2017 InformationCopyright 2017, Mary Ann Liebert, Inc.To cite this article:Christopher M. Holman.For Monoclonal Antibodies, Compliance with the Written Description Requirement Has Become a Moving Target.Biotechnology Law Report.Dec 2017.273-283.http://doi.org/10.1089/blr.2017.29043.cmhPublished in Volume: 36 Issue 6: December 1, 2017PDF download